Categories: NewsPharmaceutical

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Live video webcast on Wednesday, October 2nd at 12:00 PM ET

LA JOLLA, CA, Sept. 25, 2024 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in a Virtual Investor CEO Connect segment on October 2, 2024 at 12:00 PM ET.

As part of the event, Dr. Hertz will provide a brief presentation, followed by an interactive Q&A session. Investors and interested parties will have the opportunity to submit questions live during the event. Questions can also be pre-submitted leading up to the event by emailing GRI@jtcir.com. Time permitting, the Company will respond to submitted questions.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (gribio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About GRI Bio, Inc.

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com

Staff

Recent Posts

Tariff Uncertainty Disrupts Healthcare Operations: New Diagnostic Survey Highlights Staffing Changes, Delayed Purchases, and Supply Chain Strain

ARLINGTON, Va., June 26, 2025 /PRNewswire/ -- A new survey of 195 diagnostic imaging and…

47 minutes ago

Ultima Genomics Selected to Support the World’s Largest Proteomics Studies to Date Led by Regeneron Genetics Center

FREMONT, Calif., June 26, 2025 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new…

47 minutes ago

Therap Enhances Secure Document Signing with Added ‘Order’ Module Search Option in Reference Module Dropdown

TORRINGTON, Conn., June 26, 2025 /PRNewswire/ -- Therap Services, the leading provider of HIPAA-compliant electronic documentation…

47 minutes ago

Los Angeles Center for Ear, Nose, Throat and Allergy Introduces Clarity Technologies’ New Audiology Video Library

Cutting-edge tool aims to enhance patient education and experience while improving operational efficiency LOS ANGELES,…

47 minutes ago

MyndTec Announces Results of Annual General and Special Meeting of Shareholders

Mississauga, Ontario--(Newsfile Corp. - June 26, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the…

2 hours ago

Canadian Institute of Actuaries Announces Alicia Rollo as New Executive Director

Ottawa, Ontario--(Newsfile Corp. - June 26, 2025) - As the Canadian Institute of Actuaries (CIA)…

7 hours ago